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A B S T R A C T
Background
Acute sinusitis is a common reason for primary care visits. It causes significant symptoms and often results in time off work and school.
Objectives
We examined whether intranasal corticosteroids (INCS) are effective in relieving symptoms of acute sinusitis in adults and children.
Search methods
We searched CENTRAL 2013, Issue 4, MEDLINE (January 1966 to May week 2, 2013), EMBASE (1990 to May 2013) and
bibliographies of included studies.
Selection criteria
Randomised controlled trials (RCTs) comparing INCS treatment to placebo or no intervention in adults and children with acute
sinusitis. Acute sinusitis was defined by clinical diagnosis and confirmed by radiological evidence or by nasal endoscopy. The primary
outcome was the proportion of participants with either resolution or improvement of symptoms. Secondary outcomes were any adverse
events that required discontinuation of treatment, drop-outs before the end of the study, rates of relapse, complications and return to
school or work.
Data collection and analysis
Two review authors independently extracted data, assessed trial quality and resolved discrepancies by consensus.
Main results
No new trials were found for inclusion in this update. Four studies involving 1943 participants with acute sinusitis met our inclusion
criteria. The trials were well-designed and double-blind and studied INCS versus placebo or no intervention for 15 or 21 days. The
rates of loss to follow-up were 7%, 11%, 41% and 10%. When we combined the results from the three trials included in the meta-
analysis, participants receiving INCS were more likely to experience resolution or improvement in symptoms than those receiving
placebo (73% versus 66.4%; risk ratio (RR) 1.11; 95% confidence interval (CI) 1.04 to 1.18). Higher doses of INCS had a stronger
effect on improvement of symptoms or complete relief: for mometasone furoate 400 µg versus 200 µg (RR 1.10; 95% CI 1.02 to 1.18
versus RR 1.04; 95% CI 0.98 to 1.11). No significant adverse events were reported and there was no significant difference in the drop-
out and recurrence rates for the two treatment groups and for groups receiving higher doses of INCS.
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Authors’ conclusions
Current evidence is limited for acute sinusitis confirmed by radiology or nasal endoscopy but supports the use of INCS as amonotherapy
or as an adjuvant therapy to antibiotics. Clinicians should weigh the modest but clinically important benefits against possible minor
adverse events when prescribing therapy.
P L A I N L A N G U A G E S U M M A R Y
Steroids for acute sinusitis in adults and children
Acute sinusitis is a common reason for primary care visits; it is one of the 10 most common diagnoses in outpatient clinics, presenting
with various symptoms and signs that include purulent nasal discharge and congestion and cough lasting beyond the typical seven to
10 days of a viral upper respiratory infection. There have been suggestions, based on studies of allergic rhinitis and chronic sinusitis,
that intranasal corticosteroids (INCS) may relieve symptoms and hasten recovery in acute sinusitis due to their anti-inflammatory
properties.
A critical systematic review of the literature found four well-conducted, randomised, placebo-controlled intervention studies, involving
1943 participants treated for 15 or 21 days. The results suggest that there may be a modest effect with INCS in the resolution or
improvement of symptoms. Only minor adverse events such as epistaxis, headache and nasal itching were reported. Given the small
number of studies included in this review, it is recommended that further randomised controlled trials be conducted. The evidence is
up to date as of May 2013.
B A C K G R O U N D
Description of the condition
Acute sinusitis is a common reason for primary care visits. It causes
significant symptoms andoften results in time off work and school.
It is one of the 10 most common diagnoses in ambulatory practice
and is the fifth most common diagnosis for which an antibiotic
is prescribed. Primary care physicians tend to think of sinusitis as
an acute bacterial infection and consequently prescribe antibiotics
in 85% to 98% of cases. However, sinusitis is frequently caused
by a viral infection. According to epidemiological estimates, only
0.2% to 2% of viral upper respiratory tract infections in adults
are complicated by bacterial rhinosinusitis. It will often resolve in
most patients without antibiotic treatment, even if it is bacterial in
origin. Since no simple and accurate practice-based test exists for
acute bacterial sinusitis, clinicians rely on clinical findings to make
the diagnosis. Signs and symptoms of acute bacterial sinusitis and
those of prolonged viral upper respiratory tract infection are very
similar, resulting in frequent misclassification of viral cases (Snow
2001).
The commoncold is associatedwith frequent and variable anatom-
ical involvement of the upper airways, including occlusion and
abnormalities in the sinus cavities (Gwaltney 1994). Rhinorrhoea,
sinus tenderness, purulent secretions and a history of sinusitis were
significant predictors for the diagnosis of sinusitis in a retrospec-
tive analysis (Little 2000). Acute sinusitis is defined as an inflam-
mation of the sinuses with the symptom complex lasting less than
eight weeks in adults and less than 12 weeks in children (Kaliner
1997).
Clinical diagnosis is made through the appearance of a characteris-
tic constellation of symptoms and signs, including purulent nasal
discharge and congestion and cough lasting beyond the typical
seven to 10 days for a viral upper respiratory infection. Fever and
facial pain may also occur. Diagnosis is often confirmed by sinus
imaging; in this area, the use of computerised tomography (CT)
scanning is gaining favour (Gwaltney 1995).
Inflammation of nasal mucosa plays an essential role in the devel-
opment of sinusitis (Tutkun 1996). Sinusitis is invariably accom-
panied by inflammation of the contiguous nasal mucosa, there-
fore rhinosinusitis has become the preferred term (Snow 2001).
The precipitating factor in acute sinusitis appears to be blockage
of the sinus ostium. The obstruction, as well as mucus retention
and infection, produce the characteristic signs and symptoms of
rhinosinusitis. Although many conditions may lead to ostial clo-
sure, viral upper respiratory infections and allergic inflammation
are by far the most frequent and important (Shapiro 1992).
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Description of the intervention
Treatment of sinusitis is aimed at eliminating causative factors and
controlling the inflammatory and infectious components (Becker
2003). It has been theorised that by decreasing the inflamma-
tory response and reducing the mucosal swelling, a topical in-
tranasal steroid would promote drainage and increase aeration
of the sinuses, thus hastening the elimination of infectious or-
ganisms and decreasing the frequency and severity of recurrences
(Mygind 1976). There is evidence that asthma, otitis media with
effusion and acute sinusitis may all benefit from such therapy as
well (Scadding 2000). A recent Cochrane review found that sys-
temic corticosteroids as adjunctive to antibiotic treatment were
effective for the short-term relief of symptoms in acute sinusitis;
the authors mention that the data for this review are limited and
there is a significant risk of bias (Venekamp 2011).
How the intervention might work
In addition to treating seasonal and perennial rhinitis (possible
predisposing factors to the development of acute rhinosinusitis),
intranasal corticosteroids (INCS) might be beneficial in reducing
inflammation in the treatment of sinusitis and may help decrease
secondary rhinovirus infections (Gawchik 2000). Themode of ac-
tion of INCS is complex. It is not known whether INCS penetrate
the nasal mucosa or act on target cells. However, their low systemic
activity supports the concept of local action on nasal mucosa. This
local effect can influence a variety of inflammatory cells and their
mediators such as epithelial cells, lymphocytes, basophiles, mast
cells and Langerhans cells. Corticosteroid-induced inhibition of
the immunoglobulin E dependent release of histamine is a possi-
ble but unproven mode of action (Mygind 2001).
Why it is important to do this review
The management of rhinosinusitis depends on a number of vari-
ables related to the duration and severity of symptoms in the
individual patient. Since there are a variety of conservative and
pharmacological interventions available, the physician can find it
difficult to develop a cohesive and logical approach to treatment
(Benninger 1997). A small benefit for clinical outcomes was ob-
served in patients treated with antibiotics for uncomplicated acute
sinusitis; 80%of participants treatedwithout antibiotics improved
within two weeks (Ahovuo-Saloranta 2011). No clear evidence
of efficacy of decongestants, antihistamines and nasal irrigations
for acute sinusitis in children was found in a recent Cochrane
Review (Shaikh 2012). Recent practice guidelines for the diag-
nosis and management of rhinosinusitis suggest considering the
use of INCS as adjunctive therapy (Slavin 2005; Spector 1998).
Although the guidelines reflect the belief of many clinicians that
INCS are a valuable component of rhinosinusitis management,
limited clinical data are available on their use in this disease. A
recent experimental prospective study on rabbits with surgically
introduced sinusitis demonstrated no clear advantage of steroids
in the treatment of sinus infections using this model (Cable 2000).
The use of adjunctive medications for acute sinusitis such as anti-
histamines, decongestants and nasal steroids also remains contro-
versial (Shrum 2001). Several recent studies tested the effective-
ness of inhaled steroids for relieving symptoms in acute sinusitis in
humans, concluding that this treatment is effective. A systematic
review that addresses the effectiveness of this therapy will provide
useful information to all primary care practitioners and could assist
in formulating the best treatment plan for the individual patient.
O B J E C T I V E S
We examined whether intranasal corticosteroids (INCS) are effec-
tive in relieving symptoms of acute sinusitis in adults and children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing topical intranasal
steroids with placebo or no intervention.
Types of participants
1. Children and adults, irrespective of age, with acute sinusitis.
2. Acute sinusitis is defined by clinical diagnosis and nasal
endoscopy or radiological evidence or nasal endoscopy.
3. We included trials including a mixed population of acute
and non-acute sinusitis if outcomes were reported separately for
these subgroups.
Types of interventions
Studies which used intranasal corticosteroids (INCS) - any prepa-
ration, dose or route of administration (for example, inhaled or
drops) versus placebo or no intervention in the control group. We
included trials reporting combined interventions only if the con-
trol arm received the same co-treatments as the intervention arm,
except for topical steroids.
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Types of outcome measures
Primary outcomes
1. Proportion of participants with resolution or improvement
of symptoms.
Secondary outcomes
1. Any adverse event that necessitated discontinuation of
treatment.
2. Proportion of participants that developed complications.
3. Drop-outs before the end of the study.
4. Rates of relapse in symptoms.
5. Proportion of participants that returned to school or work
within a specific time frame.
Search methods for identification of studies
Electronic searches
For this update we searched the Cochrane Central Register
of Controlled Trials (CENTRAL) 2013, Issue 4, part of The
Cochrane Library, www.thecochranelibrary.com (accessed 22 May
2013), which contains the Cochrane Acute Respiratory Infections
Group’s SpecialisedRegister;MEDLINE (April 2011 toMayweek
2, 2013) and EMBASE (April 2011 to May 2013). See Appendix
1 for details of previous searches.
We searched MEDLINE and CENTRAL using the following
search strategy. We combined the MEDLINE search with the
Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format (Lefebvre 2011). We
adapted the strategy to search EMBASE (Appendix 2).
MEDLINE (OVID)
1 exp Sinusitis/
2 sinusit*.tw.
3 (rhinosinusit* or nasosinusit*).tw.
4 or/1-3
5 exp Steroids/
6 steroid*.tw.
7 exp Adrenal Cortex Hormones/
8 adrenal cortex hormone*.tw.
9 exp Anti-Inflammatory Agents/
10 anti-inflammat*.tw.
11 corticosteroid*.tw.
12 or/5-11
13 exp Administration, Intranasal/
14 exp Administration, Topical/
15 (nasal* or intranasal* or topical*).tw.
16 or/13-15
17 12 and 16
18 4 and 17
Searching other resources
We inspected the reference lists in all identified studies for fur-
ther relevant studies. We also scrutinised the existing review liter-
ature (for example, Mucha 2003). We contacted trial authors for
information about possible unpublished studies. There were no
language or publication restrictions. We also searched the WHO
ICTRP and ClinicalTrials.gov trials registries (14 May 2013) for
completed and ongoing trials.
Data collection and analysis
Selection of studies
The two review authors independently reviewed the abstracts of
potential studies to be included in the review. We obtained the
full article and independently inspected it for relevance.
Data extraction and management
The two review authors independently extracted data from in-
cluded trials.We documented disagreements and resolved themby
discussion. We contacted the trial authors for clarification when
necessary. We also documented justification for excluding studies
from the review in the Characteristics of excluded studies table.
We reported on the following domains.
1. Characteristics of trials: publication status, year, country of
study, setting, design, inclusion and exclusion criteria,
recruitment, methods, analysis, results.
2. Characteristics of participants: study population, number
of participants in each group, age, gender, nationality, diagnostic
criteria.
3. Characteristics of interventions: preparation used, dose,
length of treatment and follow-up, compliance, co-interventions.
4. Outcomes: resolution of symptoms, improvement of
symptoms, relapse, complications, return to school/work,
adverse events related to the intervention, drop-outs before the
end of the study and reasons for dropping out.
Assessment of risk of bias in included studies
The two review authors independently assessed the methodolog-
ical quality of each study in the ’Risk of bias’ tables, as outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011):
1. random sequence generation;
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2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete out come data;
6. selective reporting; and
7. other bias.
We included trials if theymet the following criteria: randomisation
method described that would not allow the investigator/partici-
pant to know or influence intervention group before the eligible
participant entered in the study (low risk of bias) and randomisa-
tion stated but no information on method used is available (mod-
erate risk of bias). There were no disagreements and we observed
no selective reporting or other potential bias. We obtained addi-
tional information from the trial authors when the publications
presented insufficient detail.
Measures of treatment effect
We analysed dichotomous data by calculating the risk ratio (RR)
and risk difference (RD) for each trial with the uncertainty in
each result being expressed as 95% confidence interval (CI). We
expressed the results using the approach recommended in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).We performed all analyses on the basis of intention-to-treat
(ITT).We divided study data as far as possible from published and
unpublished information into subgroups for children less than 18
years, adults and co-interventions. We planned subgroup analyses
to assess the impact of these possible sources of heterogeneity. We
used the fixed-effect model for combining studies in the absence
of heterogeneity.
Unit of analysis issues
We included RCTs with standard designs and parallel groups in
the review.
Dealing with missing data
We tried to contact study authors for missing data.
Assessment of heterogeneity
We assessed heterogeneity by inspection of the graphical presen-
tations and I2 statistic for heterogeneity.
Assessment of reporting biases
Wedid not have sufficient studies for performing funnel plot anal-
ysis to assess possible publication bias. We did not observe other
reporting bias.
Data synthesis
We did not find any evidence of heterogeneity between studies as
assessed by inspection of the graphical presentations; therefore we
used the fixed-effect model for combining the studies.
Subgroup analysis and investigation of heterogeneity
Wedid not perform the planned subgroup analyses as the included
studies did not report data for these subgroups.
Sensitivity analysis
Weplanned no sensitivity analyses in the absence of heterogeneity.
R E S U L T S
Description of studies
Results of the search
We did not identify any trials to include or exclude in this 2013
update from the 82 new references identified. In the previous re-
view (Zalmanovici Trestioreanu 2011) 495 references were iden-
tified and the abstracts were inspected by the two review authors.
Included studies
Four studies with 1943 participants assigned to intranasal corti-
costeroids (INCS) or placebo met the inclusion criteria for this
review. Three studies were multicentre trials; one was conducted
at 22 sites - 12 primary care and 10 otolaryngology clinics (Dolor
2001), one study involved outpatients from 61 treatment centres
in the USA (Nayak 2002), one study was conducted at 71 medical
centres in 14 countries (Meltzer 2005) and one study involved
participants from theMarmara University Hospital Pediatric Out-
patient Clinic (Barlan 1997).
One trial had three treatment arms; two arms for different doses
of INCS and one arm for placebo (Nayak 2002). One trial had
four treatment arms; two arms for different doses of INCS, one
arm for antibiotic and one arm for placebo (Meltzer 2005). We
performed meta-analyses for treatment arms using different doses
of INCS combined and separately.
Participants
Participants included in the trials were children and adults with a
documented episode of acute sinusitis, confirmed by radiology or
nasal endoscopy. The entry criteria in the trials were similar.
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Intervention
All the studies used a placebo in the control group. Participants in
the treatment groups in three studies received INCS for 21 days
as fluticasone propionate two puffs daily in each nostril, giving a
total dose of 200 µg (Dolor 2001), MFNS (mometasone furoate)
twice daily giving a total dose of 400 µg or 800 µg (Nayak 2002)
and budesonide 50 µg twice daily to each nostril as a nasal spray
(Barlan 1997) as adjuvant therapy to antibiotics. One study used
MFNS 200 µg and 400 µg total daily dose in the treatment arms
for 15 days as monotherapy (Meltzer 2005). Other concomitant
therapies were similar in all groups, in every study.
Outcomes
The included studies reported the proportion of participants with
clinical success; the length of time until clinical success; differ-
ence over time in sinusitis symptoms; quality of life scores; re-
lapse (Dolor 2001); improvement in total and individual symp-
toms scores; onset of relief and evaluation of changes in comput-
erised tomography (CT) sinus scans (Nayak 2002); difference in
weekly symptom scores as difference between groups or change
from baseline (Barlan 1997); global response to treatment; time to
onset of action; meanmajor symptom scores; mean total symptom
scores; individual symptom scores; treatment failure and disease
recurrence (Meltzer 2005). Information on adverse events that oc-
curred during the trials is presented in Table 1. Drop-outs before
the end of the study and the reasons for leaving were described
in all the studies. One study did not report separate data for the
groups for this outcome and the number of participants initially
randomised in each group had a high drop-out rate. It reported
results as medians of scores using non-parametric tests because a
wide range of scores were without normal distribution; it was not
included in the meta-analyses (Barlan 1997).
Excluded studies
We excluded 491 studies for one or more of the following rea-
sons: not acute sinusitis; not randomised; observational studies;
intervention of interest not used; no relevant outcomes reported;
repeated reports of the same study; and review articles. Thirteen
reports were considered potentially eligible for inclusion but after
inspection of the full papers, we excluded nine (Bachert 2007;
Gehanno 2000; Jurkiewicz 2004; Meltzer 1993; Meltzer 2000;
Quarnberg 1992; Tutkun 1996; Williamson 2007; Yilmaz 2000)
(see Characteristics of excluded studies table). In the first publica-
tion of this review (Zalmanovici 2007) two studies were awaiting
further assessment for missing data (Meltzer 2000; Tutkun 1996).
We excluded these studies in the first update (Zalmanovici 2009) as
data were not made available from the trial authors, whomwe con-
tacted. The reasons for exclusion are added to the Characteristics
of excluded studies table. In addition, for one study (Jurkiewicz
2004), no abstract or full paper was available.
Risk of bias in included studies
The studies were well-designed, randomised, double-blind,
placebo-controlled trials. The overall risk of bias is presented
graphically in Figure 1 and summarised in Figure 2.
Figure 1. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All four studies were RCTs. However, only two contained an ade-
quate report of the generation of allocation sequence (Dolor 2001;
Meltzer 2005) and one study reported concealment of allocation
(Dolor 2001). The assessment for trial inclusion was based on al-
location concealment.
Blinding
The trials were double-blinded and the method of blinding was
adequate. One study did not describe the method of blinding
(Barlan 1997).
Incomplete outcome data
Drop-outs before the end of the study and the reasons for leaving
were described in the studies. The total loss to follow-up was 7%
(Dolor 2001), 11% (Nayak 2002), 10% (Meltzer 2005) and 41%
(Barlan 1997), respectively.
Selective reporting
The studies reported what was pre-stated in their protocol.
Other potential sources of bias
We identified no other sources of bias.
Effects of interventions
Four studies that included 1943 participantsmet our inclusion cri-
teria (Barlan 1997; Dolor 2001;Meltzer 2005; Nayak 2002). Two
studies had more than two arms, two treatment arms for differ-
ent doses of intranasal corticosteroids (INCS), and we performed
separate and combined dose meta-analyses (Meltzer 2005; Nayak
2002). One study was included in the review but not in the meta-
analysis as it was not possible to extract data, non-parametric tests
were used and it had a high drop-out rate (Barlan 1997).
Primary outcome
Proportion of participants with resolution or improvement
of symptoms
Information on our primary outcome was found in three trials,
assessed at 15 days in one study (Meltzer 2005) and at 21 days
in two other studies (Dolor 2001; Nayak 2002). When combined
using intention-to-treat (ITT) analysis, 73% of INCS-treated par-
ticipants and 66.4% of controls had resolution or marked im-
provement of symptoms (for every 100 patients treatedwith INCS
seven additional patients had complete or marked symptom re-
lief ). Individuals treated with INCS (combined results for the 200
µg, 400 µg and 800 µg doses) were more likely to have complete
relief or improvement than the placebo group (risk ratio (RR)
1.11; 95% confidence interval (CI) 1.04 to 1.18) (Analysis 1.3);
(risk difference (RD) 0.07; 95% CI 0.03 to 0.11) and this result
was statistically significant. When we performed separate meta-
analyses for different doses of INCS, a stronger and statistically
significant effect was obtained when patients were treated with
400 µg than 200 µg mometasone furoate (MFNS) total daily dose
(RR 1.10; 95% CI 1.02 to 1.18 versus RR 1.04; 95% CI 0.98
to 1.11) (Analysis 1.1; Analysis 1.2); (RD 0.06; 95% CI 0.02 to
0.11 versus RD 0.04; CI 95% -0.02 to 0.09). The attributable risk
percentage (AR%) calculated for the results that were statistically
significant means that 8% (one in 12) of all patients who, having
received the 400 µg dose of INCS, had resolution or improvement
in symptoms could attribute that relief to the treatment. When
calculated from results combined across all doses, the number is
9% (one in 11). One study that used in one of the treatment arms
an 800 µg MFNS daily dose found a statistically significant effect
for this dose (RR 1.21; 95% CI 1.05 to 1.39) (Nayak 2002).
Secondary outcomes
Any adverse event that necessitated discontinuation of
treatment
This outcome was reported in two studies (Meltzer 2005; Nayak
2002). No separate data for each treatment arm were available in
one study (Nayak 2002) and the participants were equally dis-
tributed among the three arms. One study reported a drop-out
rate from treatment of 1%, 3%, 2% and 2% because of adverse
events in the INCS 200 µg, 400 µg, antibiotic and placebo arms
(Meltzer 2005) (Table 1).
Proportion of participants that developed complications
No studies reported this outcome.
Drop-outs before the end of the study
This outcome is reported in three studies (Dolor 2001; Meltzer
2005; Nayak 2002). No statistically significant difference could
be found for participants that were lost to follow-up in the two
groups (RR 0.85; 95% CI 0.64 to 1.12) (Analysis 1.6). Using a
higher dose of INCS did not change the results (RR 0.86; 95%
CI 0.61 to 1.20) (Analysis 1.4) for MFNS 400 µg versus MFNS
200 µg (RR 0.75; 95% CI 0.46 to 1.21) (Analysis 1.5).
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Rates of relapse in symptoms
Two studies reported data for this outcome (Dolor 2001; Meltzer
2005). No statistically significant differences could be found be-
tween groups; 6.3% and 10%had relapse in the INCS and placebo
groups (RR 0.71; 95% CI 0.44 to 1.15) (Analysis 1.7). The me-
dian time to first recurrence was three days earlier in the placebo
group (22 versus 25 days) in one study (Dolor 2001). One study
did not find significant differences between groups for different
doses of INCS (Meltzer 2005).
Proportion of participants that returned to school or work
within a specific time frame
No studies reported this outcome. One study (Dolor 2001) re-
ported a higher subjective level of work performance that was sig-
nificantly different on day 21 (P value = 0.009) in the INCS treat-
ment group versus placebo. The difference between groups with
respect to the total number of hours missed from work was not
significant (P value = 0.40).
D I S C U S S I O N
Acute sinusitis is typically first seen as an upper respiratory tract
infection that has persisted beyond five to seven days. The diag-
nosis of sinusitis is based on a combination of clinical history with
physical examination, nasal cytology or imaging studies (or both).
Factors that may predispose to sinusitis include allergic or occupa-
tional rhinitis, vasomotor rhinitis, nasal polyps, rhinitis medica-
mentosa and immunodeficiency (Spector 1998). Although acute
sinusitis is an infectious disease in which several bacterial species
play a major aetiological role, there is an important interaction
between respiratory viruses (for example, common cold viruses)
and bacteria in the pathogenesis of acute community-acquired si-
nusitis (Winther 1990). Upper respiratory tract infections and al-
lergic inflammation are recognised as the important risk factors
for acute sinusitis, with upper respiratory tract infection being the
most common (Wald 1988).
Summary of main results
Four studies met the inclusion criteria in our review. They were
well-conducted and produced results that suggest a clinically rel-
evant, earlier resolution of symptoms in participants treated with
intranasal corticosteroids (INCS), without the risk of severe ad-
verse events, even when higher doses in the therapeutic range were
used. All four of the trials reached statistical significance for this
outcome. One in 12 of all patients who having received the 400
µg dose had resolution or improvement in symptoms could at-
tribute that relief to the treatment. Across all doses, the number
is one in 11. No statistically significant difference in the relapse
rate between groups was found. One study (Barlan 1997) found
that INCS may be a useful ancillary treatment to antibiotics in
childhood sinusitis and effective in reducing the cough and nasal
discharge earlier in the course of acute sinusitis. Clinical signs and
symptoms decreased significantly in both groups in comparison
to baseline (P < 0.01) and in the intervention group when com-
pared to placebo in the scores for cough and nasal discharge at the
end of the second week (P < 0.05). This study was not included
in the meta-analyses as it had a high drop-out rate (41%), drop-
outs were not described separately for both groups, outcomes were
reported as weekly scores using non-parametric tests and it was
not possible to extract data for our outcomes. One of the included
studies (Nayak 2002) found a significant improvement in the to-
tal symptom score and in individual symptom scores during the
treatment period.
The mean change in the score from computerised tomography
(CT) scans of the sinuses from baseline to day 21 was not sta-
tistically significant between the treatment and control groups.
One other included study (Dolor 2001) found the median num-
ber of days to clinical success in those treated with INCS was
six days compared to nine and a half days in those treated with
a placebo. The subjective level of work performance at 21 days
was significantly better in the treatment group. Improvement in
sinusitis symptoms scores, sinusitis-related quality of life and the
total number of hours of workmissed were not significantly differ-
ent in the two groups. Mometasone furoate (MFNS) 400 µg daily
demonstrated significant superiority over MFNS 200 µg daily in
nasal congestion/stuffiness score (P = 0.013) and global response
to treatment (P = 0.002) was more consistently superior across
the endpoints and over amoxicillin in one study (Meltzer 2005),
suggesting that higher doses are needed. Also, this study found
significant improvement in the major symptom score (P < 0.001),
total symptom score (P < 0.001), global response to treatment (P
= 0.001) and individual symptom scores (rhinorrhoea, nasal con-
gestion/stuffiness, sinus headache, facial pain) for MFNS 400 µg
over placebo.
The results of these studies and reviews support the current clin-
ical rationale of adding an INCS to antibiotic therapy for acute
episodes of rhinosinusitis and suggest that higher doses are needed;
effectiveness as monotherapy remains to be demonstrated by fur-
ther studies. The included studies enrolled adults and children
and the samples were representative of participants that physi-
cians would recognise as common in their practice. Clinical im-
provement was assessed by patient-derived (subjective) symptom
reports and this outcome met one of our study goals: evaluating
alleviation of symptoms together with possible adverse events.
Overall completeness and applicability of
evidence
It is important that the mucous membranes and ciliary function
are restored to normal as soon as possible, to avoid recurrence or
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development of chronic sinusitis (Quarnberg 1992). Two surveys
of primary care and specialty physicians suggested considerable
variability in approaches to treatment (Piccirillo 2001; Williams
1993). Recommendations for appropriate treatment for acute si-
nusitis range from symptomatic treatment alone (Snow 2001) to
a prolonged course of antibiotic therapy (Winther 1990). A va-
riety of ancillary treatments aimed at improving nasal and sinus
ostial patency (antihistamines, decongestants, INCS and nasal ir-
rigation) might be helpful in the treatment of sinusitis but there
are few controlled studies to support or deny their effectiveness
(Zeiger 1992). Numerous clinical trials attest to the efficacy of
topical corticosteroids in controlling symptoms of allergic rhinitis
(Juniper 1990; Seigel 1988). The similarity of the respiratory ep-
ithelium in the nose and paranasal sinuses, as well as the contiguity
of these areas, would lead one to expect that sinusitis might also
be treatable with inhaled corticosteroids.
Whether nasal steroid therapy can sufficiently decrease nasal in-
flammation and improve mucociliary transport to the point where
the ostiomeatal complex becomes competent is unknown. Top-
ical corticosteroids offer the theoretical advantage of a localised
therapeutic action in nasal tissues, without the occurrence of un-
desirable systemic effects (Sahay 1980). Inhaled corticosteroids
have been used safely in patients with allergic rhinitis or asthma.
There exists a theoretical concern regarding the potential spread
of infection in acute sinusitis. However, this does not occur when
topical corticosteroids are administered concurrently with antibi-
otics (Druce 1990; Druce 1991). Investigations of whether INCS
promotes resolution of symptoms and prevents recurrences of si-
nusitis have yielded conflicting results (Meltzer 1993; Quarnberg
1992).
Acute sinusitis is a very common infection in childhood but its
management remains a controversial issue. A considerable propor-
tion of children, especially those with mild or improving symp-
toms, may not have to be treated at all (Contopoulos 2003). Man-
agement of acute sinusitis usually includes an oral antibiotic.How-
ever, it has been estimated that about 45% of cases will resolve
without antibiotics (Spector 1998).
Considering the host of symptoms associated with acute rhinosi-
nusitis, recovery can take time and be of substantial discomfort to
the affected patient. The burden of affected individuals in terms
of decreased productivity, absenteeism from the workplace and
diminished quality of life, when added to the cost of care and
the growing public health menace of antibiotic-resistant bacteria,
makes rhinosinusitis a serious disease that warrants a precise di-
agnosis and effective therapy. Recognised pitfalls in acute rhinosi-
nusitis management are the injudicious use of antibiotics and an-
tihistamines (Winstead 2003). The decision on the best treatment
for the specific patient should be based on the severity of symp-
toms, adapted individually, taking in consideration the existing
evidence and the patient’s preferences.
Most clinicians diagnose acute sinusitis using only clinical symp-
toms, without additional diagnostic tests. Over-diagnosis of acute
bacterial rhinosinusitis is not surprising, considering the lack of
specific clinical features that distinguish it from non-bacterial up-
per respiratory tract infections. Often, patients and physicians be-
lieve that an upper respiratory tract infection has gone on too
long and that antibiotic treatment is therefore needed. Symp-
tomatic treatment and reassurance are the preferred initialmanage-
ment strategy for patients withmild symptoms. Antibiotic therapy
should be reserved for patients with severe symptoms who meet
the criteria for the clinical diagnosis of acute bacterial rhinosinusi-
tis, regardless of the duration of the illness. The greatest barrier
to efficient antibiotic treatment of acute bacterial rhinosinusitis is
the lack of a simple and accurate diagnostic test. Until a better
test is widely available in clinical practice, the primary diagnosis of
acute bacterial rhinosinusitis will remain imprecise (Snow 2001).
Quality of the evidence
Currently, nasal steroid therapy has become an acceptable adjunct
in treating both acute and chronic sinusitis. Several intranasal
steroids are now available: flunisolide, beclomethasone, triamci-
nolone, fluticasone, budesonide and mometasone. Each of these
has proven to be effective in the treatment of allergic rhinitis and
may be a useful addition in sinus disease (Spector 1998). The
International Consensus Conference Proceedings on Rhinitis recom-
mends the use of INCS as a first-line therapy, since they have
been found to be well-tolerated and effective withminimal adverse
events (Gawchik 2000).
The evidence available suggests that some intranasal steroids, such
as beclomethasone dipropionate, may slow growth when used reg-
ularly for prolonged periods (Allen 2000). Studies of MFNS in
adults and children with allergic rhinitis showed a lack of hy-
pothalamic-pituitary axis suppression, no childhood growth sup-
pression and were consistent with extremely low bioavailability
of MFNS after intranasal administration (Brannan 1997; Davies
1997; Schenkel 2000). Reducing the systemic activity of nasal
corticosteroids to the lowest possible level is desirable. Pharmaco-
logically, newer drugs such as MFNS and fluticasone propionate
appear to have substantially higher topical potencies, higher lipid
solubilities and lower systemic bioavailabilities than older com-
pounds.With respect to adverse events, emerging data suggest that
MFNS and fluticasone may have less potential for systemic ef-
fects during prolonged use, particularly in children (Corren 1999).
For short-term therapy of one to two months, the first-genera-
tion INCS (beclomethasone, triamcinolone, budesonide and flu-
nisolide) could be used andMFNS and fluticasone (second-gener-
ation drugs) could be considered for long-term therapy. With the
exception of fluticasone for children aged four years and older and
MFNS for those aged three years andolder, the other INCS includ-
ing beclomethasone, triamcinolone, budesonide and flunisolide
are approved for children six years and older. All are effective, so
the major considerations are cost and safety (Galant 2001).
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The decision on the best treatment for the specific patient should
be based on the severity of symptoms, adapted individually, taking
in consideration the existing evidence and the patient’s preferences.
Potential biases in the review process
A small number of studies were included in this review and not
all reported an adequate concealment of allocation to treatment.
Agreements and disagreements with other
studies or reviews
The minor effects of inhaled corticosteroids for acute sinusitis
observed in this review are supported by other existing evidence,
including the evidence mentioned here.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current evidence supports the use of intranasal corticosteroids for
relief or improvement in clinical outcomes in acute uncomplicated
sinusitis, although data are limited and modest effects were ob-
served. There is no evidence that their use as a monotherapy or
as an adjuvant therapy would be detrimental in therapeutic doses.
The study population included in this review was diagnosed both
clinically and by radiology or endoscopy and is not necessarily
identical to the participants from the clinical practice where the
diagnosis is usually based on clinical signs and symptoms alone.
Implications for research
Given the small number of trials, additional large, randomised,
placebo-controlled trials are needed to evaluate the efficacy of in-
tranasal corticosteroids for acute sinusitis. These trials should de-
scribe adequate allocation and concealment procedures, be dou-
ble-blinded and include outcomes on work performance, return
to work and functional status, as well as assessment of different
doses of INCS, the optimal duration of treatment and the risk-
benefit ratio. Studies on participants with milder forms of acute
sinusitis receiving symptomatic treatment including INCS and
without antibiotic therapy could also be conducted, taking into
consideration the emergence of resistant organisms and adverse
events that result from the irrational use of antibiotics.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barlan 1997
Methods Randomised: method of randomisation not mentioned
Allocation concealment not mentioned
Double-blind: yes
Intention-to-treat not mentioned
Follow-up described
151 recruited; 89 (59%) completed study; 41% drop-out
Design: parallel
Participants N = 89; 42 male, 47 female
Age 1 to 15 years
Inclusion criteria: 2 of 3 major criteria - purulent nasal discharge, cough, purulent
pharyngeal drainage or 1 major and 2 minor criteria: facial pain, periorbital oedema,
earache, tooth pain, sore throat, headache, increased wheeze, fever, foul breath for more
than 7 days and Rx criteria
Water radiographs at the beginning of study positive if complete opacification or max-
illary mucoperiosteal thickening more than 4 mm. 79 participants had positive Rx
Exclusion criteria: history of allergic rhinitis, asthma, recurrent/chronic sinusitis
Baseline characteristics: similar in both groups, no significant differences
Patients maintained daily symptom cards and were examined by the same physician each
week. Symptom scores were evaluated by a scale from 0 to 3
Interventions Tx group: budesonide 50 µg bid nasal spray to each nostril, N = 43
C group: placebo nasal spray bid, N = 46
All participants in both groups received amoxicillin-clavulanate potassium 40 mg/kg/
day tid
Duration: 3 weeks
Outcomes Difference in weekly symptom scores for cough and nasal discharge in the first, second
and third week of the study in both groups, as difference between groups or change from
baseline
Relapse: results were reported as medians of scores using non-parametric tests because a
wide range of scores without normal distribution
Notes Marmara University Hospital Outpatient Clinic patients enrolled fromNovember 1993
to October 1994
Informed consent signed by all parents. 151 patients enrolled, 89 completed study, 62
dropped out, no separate data for both groups
Reasons for drop-outs: non-compliance with weekly visits or not recording daily symp-
toms
Risk of bias
Bias Authors’ judgement Support for judgement
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Barlan 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised, method not mentioned
Allocation concealment (selection bias) Unclear risk Not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No separate data for groups, ITT not men-
tioned
Selective reporting (reporting bias) Low risk No evidence of reporting bias
Other bias Unclear risk -
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -
Dolor 2001
Methods Multicentre randomisation - permuted blocks scheme stratified by site with a block size
of 4 generated using SAS version 6.12
Allocation concealment - study kits administered sequentially by blinding site personnel
to block size
Blinding: yes
Intention-to-treat: yes
Follow-up described: yes
88 (93%) completed study
Design: parallel
Participants N = 95; 30 men, 65 women
Age 30 to 50; median age 39 years
Inclusion criteria: older than 18 years, history of recurrent sinusitis or chronic rhinitis
and clinical evidence of acute sinusitis confirmed Rx or by nasal endoscopy
Diagnosis of acute sinusitis: clinical criteria - participants with 2 of the 5 following
symptoms present were enrolled: headache, facial pain, nasal congestion, thick coloured
nasal discharge, olfactory disturbance
Rx criteria: air-fluid level, mucosal thickening or opacification of sinus
Exclusion criteria: previous sinus surgery, sinus lavage in the past 7 days, nasal poly-
posis, recurrent epistaxis, chronic bacterial sinusitis with failure of antibiotic therapy,
INCS use within past 14 days, chronic use of corticosteroids or immunosuppressives,
immunocompromised, allergy to penicillin/cephalosporins, participants without a tele-
phone, pregnant, nursing women
Baseline characteristics - similar in both groups, no significant differences
Participants assessed at baseline, 10, 21, 56 days by diary records and telephone follow-
up
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Dolor 2001 (Continued)
Interventions Tx group: nasal spray fluticasone propionate 2 puffs (total dose 200 µg) once daily in
each nostril; N = 47
C group: nasal spray placebo 2 puffs once daily in each nostril; N = 48
All participants in both groups received 2 puffs xylometazoline hydrochloride in each
nostril twice daily 10 minutes before the study nasal spray and 250 mg cefuroxime axetil
twice daily for 10 days
Duration of study: 21 days
Follow-up: 8 weeks
Allowed to continue: NSAIDs, analgesics, immunotherapy for allergies, orally inhaled
corticosteroids
Not permitted during study: oral decongestants, mucolytics, corticosteroids oral or par-
enteral, antihistamines, immunosuppressives
Sinus lavage or sinus surgery was discouraged during the first 3 weeks of the trial,
antibiotic use in the past 7 days or 21 days if longer half-life was not permitted
Compliance with Tx: assessed by a standardised form given to patients for recording
daily symptoms, Tx, adverse events, work attendance. 94% completed study Tx without
difference between groups
Outcomes Proportion of patients with clinical success (cured or much improved) at 10, 21, 56 days
on telephone follow-up
Time to clinical success differences over time in sinusitis and quality of life scores
Level of work performance
Total number of hours lost from work
Recurrences
Notes Study conducted between October 1998 to April 2000 at 22 sites (12 primary care and
10 otolaryngology)
Equal proportions of participants from primary care and otolaryngology practices in
both treatment arms
All study sites received standardised instructions for conducting the study
Study progress monitored by a research associate
Patients assessed symptoms on numeric scales and received booklets with specific in-
structions for use of nasal spray
High agreement between patient-recorded and interviewer-obtained symptoms
Drop-outs:
Tx group: 1 - rash, 1 - unknown, 1 - lost to follow-up
44 completed 21-day Tx and telephone follow-up, 36 completed diary, 46 included in
primary analysis
C group: 1 - withdrew, 2 - switched to different antibiotics
45 completed 21-day Tx, 44 completed telephone follow-up, 32 completed diary, 46
included in primary analysis
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See methods
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Dolor 2001 (Continued)
Allocation concealment (selection bias) Low risk See methods
Incomplete outcome data (attrition bias)
All outcomes
Low risk See methods
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk -
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk See methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -
Meltzer 2005
Methods Multicentre randomisation
1:1:1:1 ratio to 1 of 4 arms by computer-generated code
Allocation concealment: not mentioned
Double-blind: yes
Intention-to-treat: yes
Follow-up described
10% drop-out in Tx phase, 95% completed follow-up phase
Design: parallel
Participants N = 981; 338 men, 643 women
Age 12 to 76 years
Inclusion criteria: age more than 12 years with clinical criteria for acute sinusitis; MSS
more than 5 but less than 12 at baseline, assessed by participant and investigator and no
more than 3/5 symptoms rated severe (rhinorrhoea, PND nasal congestion, stuffiness,
sinus headache and facial pain on pressure) adding cough to the TSS
Exclusion criteria: fulminant bacterial rhinosinusitis, chronic rhinosinusitis, nasal/sinus
surgery within the last 6 months for this condition, otitis, atrophic rhinitis, nasal polyps,
symptomatic seasonal allergic rhinitis, allergy to corticosteroids
Asthmatic participants needed to be stable last 30 days and FEV1 more than 65% last
3 months before screening
Rhinoscopic examination was performed at all visits
Participants were assessed at baseline days 8, 15, 29 and monitored by telephone on days
3 to 4. Response to Tx evaluated by participant and investigator as scores for symptoms
on a scale from 0 to 3
Baseline characteristics similar for all the arms
Interventions 4 groups
Tx groups:
1. MFNS 200 µg once daily nasal spray + placebo nasal spray once daily + placebo
capsules tid; N = 243
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Meltzer 2005 (Continued)
2. MFNS 200 µg nasal spray bid + placebo capsules tid; N = 235
3. amoxicillin 500 mg tid for 10 days + placebo nasal spray bid; N = 251
C group: placebo nasal spray bid + placebo capsules tid; N = 252
Duration of study: 15 days
Capsules given for 10 days
Follow-up: 14 days
Not allowed during study: nasal saline, nasal cromolyn sodium, ipratropium bromide,
corticosteroids (excluding oral inhaled corticosteroids for mild/moderate asthma), anti-
histamines, decongestants, leukotriene pathway modificants, analgesics, NSAID
Compliance assessed at days 8 and 15 by questioning whether drug had been taken
Each participant received at least 1 dose of study drug
Outcomes Mean MSS
Mean TSS
Individual scores
Time to onset of action
Global response to Tx
Adverse events
Disease recurrence
Tx failure (worsening or not improvement in symptoms during the Tx phase)
Notes Study conducted at 71 medical centres in 14 countries from January to September 2003
Drop-outs: during the Tx phase in the 200 µg, 400 µgMFNS, amoxicillin, placebo were
9%, 9%, 8%, 13%
Reasons for discontinuation: adverse events, Tx failure, loss to follow-up, did not wish
to continue, non-compliance with protocol, did not meet protocol criteria for entry
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk See methods
Allocation concealment (selection bias) Unclear risk See methods
Incomplete outcome data (attrition bias)
All outcomes
Low risk See methods
Selective reporting (reporting bias) Low risk -
Other bias Unclear risk -
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk See methods
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Meltzer 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -
Nayak 2002
Methods Multicentre, randomised; method of randomisation not mentioned
Allocation concealment not mentioned
Double-blind: yes
Follow-up described: yes
864 (89%) participants included in the primary efficacy analysis
Design: parallel
Participants N = 967; 402 men, 565 women
Age 8 to 78 years
Inclusion criteria: acute episode of rhinosinusitis, at least 1 moderate/severe nasal symp-
tom (these may include purulent rhinorrhoea, stuffiness/congestion, post-nasal drip, si-
nus headache, facial pain, cough), purulent rhinorrhoea present, sinusitis confirmed by
a CT scan, which is read by a radiologist at each study site at baseline, a total symptom
score more than 6
Exclusion criteria: nasal polyps, cystic fibrosis, Kartagener syndrome, expected immediate
sinus or nasal surgery, glaucoma, history of subcapsular cataracts, clinical significant
diseases
Symptoms evaluated at baseline (day 1) and day 21 by patient and investigator by scales.
Patients evaluated at baseline, 15, 21 days
CT scans of paranasal sinuses at baseline and 21 days evaluated by an independent
blinded radiologist
Similar baseline characteristics and baseline symptoms scores in all 3 groups
Patients recorded symptom scores, adverse events and use of medication twice daily
Interventions 3 groups
Tx groups:
1 MFNS 400 µg nasal spray twice daily; N = 324
2 MFNS 200 µg nasal spray twice daily; N = 318
C group:
Matching placebo nasal spray twice daily; N = 325
All participants in all groups received amoxicillin-clavulanate potassium 875 mg twice
daily for 21 days
Not allowedduring study: any formof corticosteroid, nasal decongestants, antihistamines
Washout period before the baseline visit for previous use of antibiotics, intranasal or
systemic corticosteroids, decongestants
Adherence to therapy assessed by weighing the nasal spray dosing containers without
patients’ knowledge
Outcomes Improvement in total symptoms score
Improvement in individual symptom score
Overall response to treatment: proportion of participants with complete or marked relief
Onset of relief
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Nayak 2002 (Continued)
Evaluation of changes in CT scans of sinuses
Adverse events
Notes Outpatients from 61 Tx centres in the US
967 participants randomised, 103 participants (11%) not included in analysis because
CT did not confirm sinusitis and excluded post-randomisation, diary data not available,
less than 80% compliance with Tx, less than 7 days Tx (32, 36, 35 in the MFNS 400,
200 µg and placebo groups)
Reasons for exclusion or discontinuation were evenly distributed among the groups
Physician evaluation of symptoms at day 21 was consistent with patient-recorded eval-
uation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk See methods
Allocation concealment (selection bias) Unclear risk See methods
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk See notes
Selective reporting (reporting bias) Unclear risk -
Other bias Unclear risk -
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk See methods
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk -
bid: twice daily
C: control
CT: computed tomography
FEV1: forced expiratory volume in one second
INCS: intranasal corticosteroid
ITT: intention-to-treat
MFNS: mometasone furoate
MSS: major symptom score
NSAID: non-steroidal anti-inflammatory drugs
PND: post-nasal drip
Rx: radiological
tid: three times daily
TSS: total symptom score
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Tx: treatment
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bachert 2007 Study on quality of life. Outcome for a subset of patients from one of the included studies (Meltzer 2005)
Gehanno 2000 Allocation: randomised, parallel
Participants: N = 433 adults with confirmed acute sinusitis
Intervention: amoxicillin-clavulanate and methylprednisolone or placebo per oral administration
No intranasal steroids used
Jurkiewicz 2004 Abstract and full paper not available
Meltzer 1993 Allocation: randomised, parallel
Participants: N = 175 participants 14 years or older with confirmed acute or chronic sinusitis
Intervention: amoxicillin-clavulanate potassium combined with nasal spray of either flunisolide or placebo
No separate arms for acute and chronic sinusitis reported
Meltzer 2000 Missing data - number randomised, numbers included in analyses, drop-outs and reasons for drop-out. The
numbers reported do not add up to 100%. An email was sent to the author but there was no reply
Quarnberg 1992 Allocation: randomised, parallel
Participants: N = 40 participants 16 years or older with confirmed recurrent or chronic sinusitis
Intervention: erythromycin and either budesonide or placebo aerosol
Separate arms for acute recurrent and chronic sinusitis were not reported
Tutkun 1996 Missing data - not mentioned acute/chronic sinusitis, diagnostic criteria not reported, drop-outs not reported.
Email was sent to the author but there was no reply
Williamson 2007 Inclusion criteria for the review were not met
Yilmaz 2000 Allocation: randomised, parallel
Participants: 52 children with confirmed acute sinusitis
Intervention: cefaclor and either oral pseudoephedrine or intranasal budesonide
No placebo used in the control group
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D A T A A N D A N A L Y S E S
Comparison 1. Intranasal corticosteroids versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Proportion of participants with
resolution of symptoms or
improved (MFNS 400 µg
daily)
2 1130 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [1.02, 1.18]
2 Proportion of participants with
resolution of symptoms or
improved (MFNS 200 µg
daily)
2 590 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.98, 1.11]
3 Proportion of participants with
resolution of symptoms or
improved (combined MFNS
200, 400 and 800 µg daily)
3 1792 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [1.04, 1.18]
4 Number of participants that
dropped out from the study
(MFNS 400 µg daily)
2 1130 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.61, 1.20]
5 Number of participants that
dropped out from the study
(MFNS 200 µg daily)
2 590 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.46, 1.21]
6 Number of participants that
dropped out from the study
(combined MFNS 200, 400
and 800 µg daily)
3 1792 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.64, 1.12]
7 Relapse (combined 200 and 400
µg daily)
2 825 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.44, 1.15]
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Analysis 1.1. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 1 Proportion of
participants with resolution of symptoms or improved (MFNS 400 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 1 Proportion of participants with resolution of symptoms or improved (MFNS 400 g daily)
Study or subgroup MFNS 400 g Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meltzer 2005 224/235 225/252 57.8 % 1.07 [ 1.01, 1.12 ]
Nayak 2002 178/318 160/325 42.2 % 1.14 [ 0.98, 1.32 ]
Total (95% CI) 553 577 100.0 % 1.10 [ 1.02, 1.18 ]
Total events: 402 (MFNS 400 g), 385 (Placebo)
Heterogeneity: Chi2 = 1.30, df = 1 (P = 0.25); I2 =23%
Test for overall effect: Z = 2.60 (P = 0.0093)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours MFNS 400 g
Analysis 1.2. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 2 Proportion of
participants with resolution of symptoms or improved (MFNS 200 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 2 Proportion of participants with resolution of symptoms or improved (MFNS 200 g daily)
Study or subgroup MFNS 200 g Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dolor 2001 39/47 30/48 11.8 % 1.33 [ 1.03, 1.71 ]
Meltzer 2005 218/243 225/252 88.2 % 1.00 [ 0.95, 1.07 ]
Total (95% CI) 290 300 100.0 % 1.04 [ 0.98, 1.11 ]
Total events: 257 (MFNS 200 g), 255 (Placebo)
Heterogeneity: Chi2 = 4.92, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 1.32 (P = 0.19)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours MFNS 200 g
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Analysis 1.3. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 3 Proportion of
participants with resolution of symptoms or improved (combined MFNS 200, 400 and 800 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 3 Proportion of participants with resolution of symptoms or improved (combined MFNS 200, 400 and 800 g daily)
Study or subgroup
MFNS
combined
200,400,800 Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dolor 2001 39/47 30/48 5.5 % 1.33 [ 1.03, 1.71 ]
Meltzer 2005 442/478 225/252 54.9 % 1.04 [ 0.99, 1.09 ]
Nayak 2002 371/642 160/325 39.6 % 1.17 [ 1.03, 1.34 ]
Total (95% CI) 1167 625 100.0 % 1.11 [ 1.04, 1.18 ]
Total events: 852 (MFNS combined 200,400,800), 415 (Placebo)
Heterogeneity: Chi2 = 9.55, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 3.26 (P = 0.0011)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Favours placebo Favours MFNS 200,400,800
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Analysis 1.4. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 4 Number of participants
that dropped out from the study (MFNS 400 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 4 Number of participants that dropped out from the study (MFNS 400 g daily)
Study or subgroup MFNS 400 g Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meltzer 2005 20/235 33/252 47.9 % 0.65 [ 0.38, 1.10 ]
Nayak 2002 36/318 35/325 52.1 % 1.05 [ 0.68, 1.63 ]
Total (95% CI) 553 577 100.0 % 0.86 [ 0.61, 1.20 ]
Total events: 56 (MFNS 400 g), 68 (Placebo)
Heterogeneity: Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours MFNS 400 g Favours placebo
Analysis 1.5. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 5 Number of participants
that dropped out from the study (MFNS 200 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 5 Number of participants that dropped out from the study (MFNS 200 g daily)
Study or subgroup MFNS 200 g Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dolor 2001 3/47 3/48 8.4 % 1.02 [ 0.22, 4.81 ]
Meltzer 2005 23/243 33/252 91.6 % 0.72 [ 0.44, 1.19 ]
Total (95% CI) 290 300 100.0 % 0.75 [ 0.46, 1.21 ]
Total events: 26 (MFNS 200 g), 36 (Placebo)
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours MFNS 200 g Favours placebo
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Analysis 1.6. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 6 Number of participants
that dropped out from the study (combined MFNS 200, 400 and 800 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 6 Number of participants that dropped out from the study (combined MFNS 200, 400 and 800 g daily)
Study or subgroup
MFNS
200,400,800
g Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dolor 2001 3/47 3/48 3.2 % 1.02 [ 0.22, 4.81 ]
Meltzer 2005 43/478 33/252 46.6 % 0.69 [ 0.45, 1.05 ]
Nayak 2002 68/642 35/325 50.2 % 0.98 [ 0.67, 1.45 ]
Total (95% CI) 1167 625 100.0 % 0.85 [ 0.64, 1.12 ]
Total events: 114 (MFNS 200,400,800 g), 71 (Placebo)
Heterogeneity: Chi2 = 1.56, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours MFNS 200,400,800 Favours placebo
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Analysis 1.7. Comparison 1 Intranasal corticosteroids versus placebo, Outcome 7 Relapse (combined 200
and 400 µg daily).
Review: Intranasal steroids for acute sinusitis
Comparison: 1 Intranasal corticosteroids versus placebo
Outcome: 7 Relapse (combined 200 and 400 g daily)
Study or subgroup MFNS 200,400 g Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dolor 2001 7/47 13/48 36.6 % 0.55 [ 0.24, 1.26 ]
Meltzer 2005 26/478 17/252 63.4 % 0.81 [ 0.45, 1.46 ]
Total (95% CI) 525 300 100.0 % 0.71 [ 0.44, 1.15 ]
Total events: 33 (MFNS 200,400 g), 30 (Placebo)
Heterogeneity: Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.17)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours MFNS 200, 400 g Favours placebo
A D D I T I O N A L T A B L E S
Table 1. Adverse events
Study Intervention Side effects Comments
Dolor 2001 Fluticasone propionate 2 puffs - to-
tal dose 200 µg or placebo nasal spray
once daily in addition to 250 mg ce-
furoxime axetil orally twice daily and
2 puffs of xylometazoline hydrochlo-
ride twice daily
Headache, bloody nose, vaginal itch-
ing, yeast infection, nausea, stomach
irritation, diarrhoea, increased con-
gestion, hay fever, light-headed, sore
throat, thirsty, itching, rash, cough,
fatigue, metallic taste, felt dried out,
nasal tissue felt inflamed
No serious unexpected adverse events
reported
Any adverse event - 37% in the flu-
ticasone group versus 20% in the
placebo group (P value = 0.7) no sta-
tistical significant difference
Adverse events could be attributed
also to the co-treatment
Nayak 2002 Amoxicillin-clavulanate potassium
875 mg
twice daily orally and MFNS 200,
400 µg or placebo nasal spray twice
daily
Epistaxis was the most frequently re-
ported adverse event
Nasal burning, irritation and
headache occurred in less than 2% of
any treatment group
Treatment well-tolerated,
adverse events similar for all 3 arms of
mild/moderate intensity: 12%, 15%,
15% in the MFNS 400, 800 µg and
placebo arms
50 patients discontinued treatment
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Table 1. Adverse events (Continued)
because of adverse events, most com-
monly diarrhoea and nausea due to
the antibiotic and were equally dis-
tributed among groups. Epistaxis,
nasal burning, irritation or infection
were not a cause for discontinuation
of treatment
Barlan 1997 Budesonide 50 µg or placebo nasal
spray to each nostril bid in addition
to amoxicillin clavulanate potassium
40 mg/kg/day tid
Rash after 1week attributed to the an-
tibiotic in 1 subject that was switched
to cefaclor
No specific adverse events related to
the INCS use were reported
Meltzer 2005 MFNS 200 µg once daily or twice
daily nasal spray
Amoxicillin 500 mg tid
Placebo nasal spray and capsules
Headache and epistaxis were most
common reported
Most adverse events were mild or
moderate with a similar incidence
among treatment groups: 36.2%,
35.4%, 33.5% and 38.1% with
MFNS 200 µg, 400 µg,
amoxicillin and placebo
1%, 3%, 2% and 2% of partici-
pants discontinued treatment because
of adverse events in the 200 µg, 400
µg INCS, antibiotic andplacebo arms
bid: twice daily
INCS: intranasal corticosteroid
MFNS: mometasone furoate
tid: three times daily
A P P E N D I C E S
Appendix 1. Previous search strategy
For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2011, Issue 2, part of The Cochrane
Library, www.thecochranelibrary.com (accessed 25 May 2011), which contains the Cochrane Acute Respiratory Infections Group’s
Specialised Register; MEDLINE (September 2008 toMay week 2, 2011) and Embase.com (October 2008 toMay 2011). See Appendix
1 for details of previous searches.
Previously we searched the Cochrane Central Register of Controlled Trials (The Cochrane Library 2008, Issue 4) which contains the
Cochrane Acute Respiratory Infections Group’s Specialised Register, MEDLINE (January 1966 to October 2008), EMBASE (1990 to
October 2008) and bibliographies of included studies.
MEDLINE was searched using the following keywords and MeSH terms in conjunction with the highly sensitive search strategy
designed by The Cochrane Collaboration for identifying randomised controlled trials (Lefebvre 2008). The same strategy was used to
search CENTRAL and adapted to search EMBASE.
MEDLINE (OVID)
1 exp SINUSITIS/
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2 sinusit*.tw.
3 rhinosinusit*.tw.
4 or/1-3
5 exp STEROIDS/
6 steroid*.tw.
7 exp Adrenal Cortex Hormones/
8 adrenal cortex hormone*.tw.
9 exp Anti-Inflammatory Agents/
10 anti-inflammat*.tw.
11 corticosteroid*.tw.
12 or/5-11
13 exp Administration, Intranasal/
14 exp Administration, Topical/
15 (nasal* or intranasal* or topical*).tw.
16 or/13-15
17 12 and 16
18 4 and 17
Appendix 2. Embase.com search strategy
#24 #16 AND #23
#23 #22 NOT #21
#22 #17 OR #18
#21 #19 NOT #20
#20 ’human’/de
#19 ’animal’/de OR ’nonhuman’/de OR ’animal experiment’/de
#18 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR allocat*:ab,ti OR trial:ti OR ((doubl* OR singl*)
NEAR/1 blind*):ab,ti
#17 ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
#16 #4 AND #11 AND #15
#15 #12 OR #13 OR #14
#14 nasal*:ab,ti OR intranasal*:ab,ti OR topical*:ab,ti
#13 ’topical drug administration’/de
#12 ’intranasal drug administration’/de
#11 #5 OR #6 OR #7 OR #8 OR #9 OR #10
#10 ’adrenal cortex hormone’:ab,ti OR ’adrenal cortex hormones’:ab,ti
#9 ’anti-inflammatory’:ab,ti OR ’anti-inflammatories’:ab,ti OR antiinflammat*:ab,ti OR ’anti inflammatory’:ab,ti OR ’anti inflamma-
tories’:ab,ti
#8 ’antiinflammatory agent’/exp
#7 ’corticosteroid’/exp
#6 steroid*:ab,ti
#5 ’steroid’/exp
#4 #1 OR #2 OR #3
#3 rhinosinusit*:ab,ti OR nasosinusit*:ab,ti
#2 sinusit*:ab,ti
#1 ’sinusitis’/exp
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WH A T ’ S N E W
Last assessed as up-to-date: 22 May 2013.
Date Event Description
22 May 2013 New citation required but conclusions have not changed Our conclusions remain unchanged.
22 May 2013 New search has been performed Searches updated. No new trials were identified in this
update
H I S T O R Y
Protocol first published: Issue 1, 2005
Review first published: Issue 2, 2007
Date Event Description
25 May 2011 New citation required but conclusions have not
changed
Searches updated. No new studies found for inclusion
or exclusion. The conclusions remain unchanged
3 June 2010 Amended Contact details updated.
28 October 2008 New citation required but conclusions have not
changed
Two trials identified in the updated search and three
trials for which data are not available were added to the
excluded studies list (Bachert 2007; Jurkiewicz 2004;
Meltzer 2000; Tutkun 1996; Williamson 2007).
28 October 2008 New search has been performed Searches conducted.
C O N T R I B U T I O N S O F A U T H O R S
Dr Anca Zalmanovici wrote the review, searched the literature, selected the studies to be included, assessed their quality, entered the
data into RevMan 2012, wrote the methods, results and discussion sections and updated the review.
Dr John Yaphe searched the literature, was an independent assessor in selecting trials to be included, assessed the quality of the trials,
wrote the discussion section and edited the review.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acute Disease; Administration, Intranasal; Adrenal Cortex Hormones [∗administration & dosage]; Randomized Controlled Trials as
Topic; Sinusitis [∗drug therapy]
MeSH check words
Adult; Child; Humans
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